araag2/HINT huggingface dataset:
Clinical trial NCT00474240 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: atorvastatin 20 mg, aegr-733 5 mg, aegr-733 10 mg, placebo, aegr-733 5 mg + atorvastatin 20 mg, aegr-733 10 mg + atorvastatin 20 mg
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Men and women between the ages of 18 and 70 years.

          2. Elevated LDL cholesterol based on risk factors for cardiovascular disease or presence
             of cardiovascular disease

        Exclusion Criteria:

          1. Women who are pregnant, lactating, planning to become pregnant, or women of
             childbearing potential who have not successfully been using acceptable contraceptive
             methods over the previous 3 months, e.g., intrauterine device (IUD) and barrier method
             plus spermicide.

          2. Uncontrolled hypertension

          3. History of chronic kidney problems

          4. History of liver disease

          5. Positive for Hepatitis B or Hepatitis C.

          6. Any major surgical procedure occurring less than 3 months ago

          7. Cardiac insufficiency

          8. History of a malignant cancer (other than basal cell or squamous cell carcinoma of the
             skin that has been removed) within the previous 5 years.

          9. Regular alcohol use >1 drink per day.

         10. Regular consumers of grapefruit juice, or currently taking the following medications:
             cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin,
             HIV protease inhibitors, and nefazodone.

         11. Use of other cholesterol lowering medications that cannot be stopped.

         12. Heart attack or stroke within the previous 6 months

         13. Diabetes Mellitus

         14. Body mass index (BMI) ≥ 40 kg/m2.

         15. Significant gastrointestinal symptoms, such as irritable bowel syndrome.

         16. Current use of fish oils, niacin, and herbal weight loss products that cannot be
             stopped.
Clinical trial NCT00547157 (phase 2, status: completed)
Conditions: cancer, head and neck cancer, oncology, squamous cell carcinoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42
Drugs: panitumumab, cisplatin
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

        Histologically or cytologically confirmed SCC of the oral cavity, oropharynx, hypopharynx
        or larynx Stage III or Stage IVa-b (M0) disease according to the American Joint Committee
        on Cancer staging manual 6th edition (locally advanced) ECOG performance status of 0 or 1
        Bidimensionally measurable disease >/= 10 mm in at least 1 dimension

        Exclusion Criteria:

        NO Primary tumor of the nasopharynx, sinuses, salivary gland, or skin NO Subjects requiring
        prophylactic tracheostomy NO Prior (or concomitant) malignancy (except non-melanomatous
        skin cancer or in situ cervical cancer), other than the study disease (SCCHN), unless
        treated with curative intent with no evidence of disease for >/= 3 years NO Prior treatment
        for locally advanced SSCHN NO Prior surgery for SCCHN (except nodal sampling or biopsy for
        study disease) NO Major surgery </= 28 days before randomization or minor surgery </= 14
        days before randomization with the exception of feeding tube placement, dental extractions,
        central venous catheter placement, biopsies and nodal sampling
Clinical trial NCT01221831 (phase 2, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: estetrol, p 1 and placebo tablets, estetrol, p2 and placebo tablets, estradiol valerate, dienogest and placebo tablets
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(O)[C@]([H])(O)[C@@]2([H])[C@]3([H])CCC4=CC(O)=CC=C4[C@@]3([H])CC[C@]2(C)[C@@]1([H])O, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Women willing to use a Combined Oral Contraceptive for 6 subsequent cycles

          -  Good physical and mental health

          -  Regular menstrual cycle (24-35 days) prior to screening

          -  Body mass index between (≥) 18 and (≤) 30 kg/m2

        Exclusion Criteria:

          -  Previous use of any hormonal contraceptive method during the last 3 months prior to
             randomisation (only applicable for women who are not using a hormonal contraceptive
             method at the time of screening)

          -  Previous use of progestogen-only contraceptive methods during the last 3 months or
             during the last 6 months for depot progestogen preparations or an injectable hormonal
             method of contraception

          -  Use of phytoestrogens

          -  No spontaneous menstruation has occurred following a delivery or abortion

          -  Breastfeeding or within 2 months after stopping breastfeeding prior to the start of
             study medication and no spontaneous return of menstruation

          -  Status post-partum or post-abortion within a period of 2 months before screening

          -  Pregnancy during accurate hormonal contraceptive use in the past

          -  Intention to become pregnant during the study

          -  An abnormal cervical smear within one year before study start

          -  Untreated Chlamydia infection

          -  Known or suspected breast cancer or a history of breast cancer

          -  A history of (within 12 months) alcohol or drug abuse

          -  Any clinically relevant abnormality

          -  Contraindications for the contraceptive steroids used in the clinical trial

          -  Use of antihypertensive drugs or use of medications interacting with the contraceptive
             steroids used in the clinical trial

          -  Administration of any other investigational drug within 2 months prior to screening
Clinical trial NCT00526669 (phase 2, status: completed)
Conditions: neoplasms, gastrointestinal tract
ICD codes: A21.3, A22.2, B46.2, K92.2, K92.81, K91.0, P54.3
Drugs: lapatinib and capecitabine
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Has signed inform consent

          -  Untreated, newly diagnosed, advanced metastatic or unresectable gastric cancer,
             including the gastro-esophageal junction

          -  Tumor accessible to and patient consent for endoscopic biopsy at study start and after
             7 days of single agent Lapatinib

          -  Measurable disease according to RECIST criteria

          -  Male or female > or = 18 years of age

          -  Cardiac ejection fraction within the institutional range of normal as measured by
             echocardiogram

          -  must have adequate organ function as defined by baseline laboratory values

        Exclusion Criteria:

          -  Gastric carcinoid, sarcomas, or squamous cell cancer

          -  Pregnant or lactating females

          -  Intractable nausea, vomiting, or gastro intestinal obstruction requiring decompression
             and drainage with a gastric tube or nasogastric suction.

          -  patients who require continuous enteral feeding

          -  Malabsorption syndrome or uncontrolled inflammatory GI disease (Crohn's or ulcerative
             colitis

          -  Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart
             failure
Clinical trial NCT00636792 (phase 2, status: completed)
Conditions: follicular lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: velcade, bendamustine, rituximab
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject 18 years of age or older

          -  Pathological diagnosis of follicular lymphoma (any grade)

          -  Documented relapse or progression following prior antineoplastic therapy

          -  Have received 4 or more prior doses of rituximab

          -  At least 1 measurable tumor mass (>1.5 cm in the long axis and >1.0 cm in the short
             axis that has not been previously irradiated, or has grown since previous irradiation

          -  No clinically significant central nervous system lymphoma

          -  Karnofsky performance status (KPS) ≥50 (equivalent to Eastern Cooperative Group
             Oncology Group [ECOG] status ≤2

        Exclusion Criteria:

          -  Diagnosed or treated for a malignancy other than non-Hodgkin's lymphoma (NHL) within 2
             years of first dose, or who were previously diagnosed with a malignancy other than NHL
             and have any radiographic or biochemical marker evidence of malignancy. Subjects with
             prostate cancer who were treated with definitive radiotherapy and have a serum
             prostate-specific antigen (PSA) <1 ng/mL are not excluded. Subjects are also not
             excluded if they have had basal cell or squamous cell carcinoma of the skin that was
             completely resected, or any in situ malignancy that was adequately treated.

          -  Prior treatment with VELCADE® or bendamustine

          -  Antineoplastic (including unconjugated therapeutic antibodies and toxin
             immunoconjugates), experimental, or radiation therapy within 3 weeks before Day 1 of
             Cycle 1

          -  Nitrosoureas within 6 weeks before Day 1 of Cycle 1

          -  Radioimmunoconjugates within 10 weeks before Day 1 of Cycle 1

          -  Autologous stem cell transplant within 3 months before Day 1 of Cycle 1, or prior
             allogeneic stem cell transplant at any time

          -  Major surgery within 2 weeks before Day 1 of Cycle 1

          -  Platelet transfusion within 7 days of Day 1 of Cycle 1 (applies to subjects enrolled
             in the dose escalation phase only. This does not apply to subjects enrolled in phase 2
             of the study).

          -  Ongoing therapy with corticosteroids. Prednisone ≤15 mg per day or its equivalent is
             allowed.
Clinical trial NCT00088634 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: lurasidone, placebo
SMILES: [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV

          -  The patient must agree to a voluntary hospitalization duration of 31 days minimum at
             the start of the treatment

          -  If female, must not be pregnant, or must be incapable of conceiving or be taking steps
             to prevent conception

        Exclusion Criteria:

          -  The patient has used an investigational drug within the past 30 days

          -  The patient has participated in a previous study of this compound
Clinical trial NCT01592786 (phase 2, status: completed)
Conditions: autism spectrum disorder (asd), autism, autistic disorder, asperger's disorder, asperger's, pediatric autism, pervasive developmental disorder not otherwise specified (pdd-nos)
ICD codes: Z13.41, F84.0, F84.5
Drugs: memantine hydrochloride (hcl)
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female outpatients.

          2. Age of 6-12.

          3. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text
             Revision (DSM-IV-TR) diagnostic criteria for autism, Asperger's Disorder, or Pervasive
             Developmental Disorder Not Otherwise Specified (PDD-NOS)

          4. Have a family that is sufficiently organized and stable to guarantee adequate safety
             monitoring and continuous attendance to clinic visits for the duration of the study

        Exclusion Criteria:

          1. Have enrolled in Study MEM-MD-57A

          2. Medical conditions that might interfere with the conduct of the study, confound
             interpretation of the study results, or endanger the patient's well-being.

          3. Participation in any other clinical investigation using an experimental drug within 30
             days of screening.

          4. Having any primary psychiatric (Axis I) diagnosis other than autism, Asperger's
             Disorder, and PDD-NOS.

          5. Meeting DSM-IV-TR criteria for bipolar I disorder, psychotic disorder not otherwise
             specified, posttraumatic stress disorder, schizophrenia, or major depressive disorder
             within the past 6 months
Clinical trial NCT00709449 (phase 2/phase 3, status: completed)
Conditions: macular degeneration, glaucoma, regional blood flow
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230, H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821
Drugs: moxaverine, moxaverine, moxaverine
SMILES: CCC1=NC(CC2=CC=CC=C2)=C2C=C(OC)C(OC)=CC2=C1, CCC1=NC(CC2=CC=CC=C2)=C2C=C(OC)C(OC)=CC2=C1, CCC1=NC(CC2=CC=CC=C2)=C2C=C(OC)C(OC)=CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women aged over 50 years

          -  Ametropia of less than 6 diopters and anisometropia of less than 2 diopters

          -  Clear non-lenticular ocular media

        AMD patients:

          -  Patients with nonexudative AMD

          -  Visual acuity in the study eye > 20/60

        Glaucoma patients:

          -  Unilateral or bilateral primary open angle glaucoma

          -  At least 3 reliable visual field testings

          -  Treated intraocular pressure < 21 mmHg,

          -  Visual field mean deviation MD <10 (Humphrey 30-2)

        Healthy control subjects:

          -  Age- , gender- and sex- matched to the two patient groups,

          -  Matched with regard to smoking habits of the two patient group

          -  No observable eye diseases

        Exclusion Criteria:

          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions
             known to interfere with distribution, metabolism or excretion of the study drug

          -  Blood donation during the previous 3 weeks

          -  Abuse of alcoholic beverages or drugs, participation in a clinical trial in the 3
             weeks preceding the study

          -  Known diabetes mellitus

          -  Presence of any ocular pathology that interferes with the aims of the present study

          -  Intraocular surgery within the last 3 weeks

          -  Hypersensitivity to moxaverine

          -  Acute gastric bleeding, massive cerebral hemorrhage related to stroke
Clinical trial NCT00546104 (phase 2, status: completed)
Conditions: advanced breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Measurable Stage IV or inoperable Stage III advanced breast cancer.

          -  There is no limit on the number of prior therapies.

          -  At least 3 weeks since prior chemotherapy, biological or hormonal therapy.

          -  At least 2 weeks since surgical biopsy.

          -  At least 3 weeks since major (open thoracic/abdominal/cardiac) surgery.

          -  No central nervous system (CNS) metastases except solitary brain metastasis

          -  No cardiac dysfunction

          -  left ventricular ejection fraction (LVEF) ≥ 50% as determined by multiple gated
             acquisition scan (MUGA)/echocardiogram

          -  Adequate blood counts

          -  Normal liver and kidney function

          -  Negative serum pregnancy test.

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Pregnant or breast feeding.

          -  Prior treatment with dasatinib.

          -  Bone as the only site of disease.

          -  Significant gastrointestinal bleeding

          -  Septicemia, infection, acute hepatitis, hypokalemia, or hypomagnesemia
Clinical trial NCT00322387 (phase 2, status: completed)
Conditions: lymphoma, non-hodgkin, multiple myeloma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C90.01, C90.02, C90.00
Drugs: g-csf and plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Eligibility criteria:

        Inclusion Criteria (Abbreviated List):

          -  MM in first partial response/complete response, first relapse, or second
             partial/complete response

          -  NHL in first or second partial or complete remission

          -  NHL patients who do not have bone marrow involvement and < 10% for follicular
             involvement

          -  MM patients who have stable disease with < 40% bone marrow involvement

          -  No more than three prior regimens of chemotherapy (thalidomide and Decadron are not
             considered chemotherapy)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  White blood cell count (WBC) >3.0 x 10^9/L

          -  Absolute neutrophil count >1.5 x 10^9/L

          -  Platelet count >100 x 10^9/L

        Exclusion Criteria (Abbreviated List):

          -  Brain metastases or carcinomatous meningitis

          -  Hypercalcaemia [>1 mg/dl above the upper limit of normal (ULN)]

          -  Cardiovascular disease that includes proven or predisposition to ventricular
             arrhythmias

          -  Acute Infection
Clinical trial NCT01324232 (phase 2, status: completed)
Conditions: central neuropathic pain, multiple sclerosis
ICD codes: E85.1, E85.0, N31.0, N31.1, N31.2, E10.610, E11.610, G35, C81.18
Drugs: avp-923, placebo
SMILES: [H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

        Multiple Sclerosis (RRMS or SPMS), Clinical history and symptoms of central neuropathic
        pain (dysesthetic pain)for at least 3 months prior to screening, PRS baseline score = or >
        4, No MS relapse within previous 30 days.

        Main Exclusion Criteria:

        Personal history of complete heart block, QTc prolongation, or torsades de pointes, family
        history of congenital QT interval prolongation syndrome, Myasthenia Gravis, BDI score > 19
Clinical trial NCT00191854 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, paclitaxel, carboplatin, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients with histological or cytological proven diagnosis of breast cancer

          -  Stage IV disease

          -  Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale

          -  Patients had to have previously received anthracycline based regimens as a adjuvant
             therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic
             disease

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior chemotherapy for metastatic disease

          -  Previous radiation therapy is allowed but must not have included whole pelvis
             radiation

          -  Known or suspected brain metastasis. Serious concomitant disorders that would
             compromise the safety of the patient or compromise the patient's ability to complete
             the study, at the discretion of the investigator

          -  Concurrent administration of any other tumor therapy, including cytotoxic
             chemotherapy, hormonal therapy and immunotherapy (including trastuzumab (Herceptin))

          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History
             of significant neurological or mental disorder, including seizures or dementia
Clinical trial NCT00263874 (phase 2, status: terminated)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: uk-500,001
SMILES: CC1=CC(C(=O)N[C@H]2CC[C@H](CC2)NC(=O)C2=C(OC3=CC(F)=C(F)C=C3)N=CC(F)=C2)=C(O)C=C1
Reason stopped: 
    the decision to terminate was completely related to efficacy and there were no safety concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate-severe COPD (Global inititiative for chronic Obstructive Lung Disease, GOLD,
             2003 definition)

          -  Smoking history of at least 10 pack-years

        Exclusion Criteria:

          -  Any significant co-morbid disease

          -  Use of any maintenance therapy except short acting bronchodilators
Clinical trial NCT00651859 (phase 2, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost 0.01% ophthalmic solution, bimatoprost 0.03% ophthalmic solution, bimatoprost vehicle ophthalmic solution
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Ethnically Japanese patients with glaucoma or ocular hypertension in each eye who
             require IOP-lowering therapy in both eyes

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Use of bimatoprost or an ocular prostaglandin (eg, latanoprost, travoprost) within 6
             weeks prior to baseline (Day 0)